摘要
目的:观察越婢加半夏汤加减联合西医综合疗法治疗支气管哮喘热哮证的临床疗效。方法:选取200例哮喘患者,按随机数字表法分为观察组和对照组各100例。对照组给予西医综合治疗,观察组在对照组基础上给予越婢加半夏汤加减治疗,2组均治疗2个月。评价2组临床疗效,比较2组治疗前后中医证候评分、肺功能、呼吸道疾病问卷修订版(AQ20-R)评分、哮喘控制问卷(ACQ-5)评分、气道高反应性、细胞间黏附分子-1(ICAM-1)及嗜酸性粒细胞(EOS)水平,并评价药物安全性。结果:观察组总有效率为97.00%,高于对照组87.00%(P<0.05)。治疗后,2组各项中医证候评分较治疗前降低(P<0.05),且观察组各项中医证候评分低于对照组(P<0.05)。治疗后,2组第1秒用力呼气容积占预计值百分比(FEV1%)、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)较治疗前升高,AQ20-R评分、ACQ-5评分均较治疗前降低(P<0.05);且观察组FEV1%、FEV1/FVC高于对照组,AQ20-R评分、ACQ-5评分低于对照组(P<0.05)。治疗后,2组FEV1下降20%所需的最低累积剂量(PD20-FEV1)高于治疗前,支气管舒张试验FEV1增加、支气管舒张试验FEV1绝对值增加、呼气峰流速昼夜变异率(PEFR)低于治疗前(P<0.05);观察组PD20-FEV1高于对照组,支气管舒张试验FEV1增加、支气管舒张试验FEV1绝对值增加、PEFR低于对照组(P<0.05)。治疗后,2组ICAM-1、EOS均低于治疗前(P<0.05),且观察组ICAM-1、EOS低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:越婢加半夏汤加减联合西医综合疗法治疗支气管哮喘热哮证临床疗效确切,能改善气道高反应性,抑制气道慢性炎症反应,提高肺功能,增强疗效,安全可靠。
Objective:To observe the clinical effect of modified Yuebi and Banxia Decoction combined with comprehensive western medicine therapy on bronchial asthma with heat-wheezing syndrome.Methods:A total of 200 patients with asthma were selected and divided into the observation group and the control group according to the random number table method,with 100 cases in each group.The control group was given comprehensive western medicine therapy,and the observation group was additionally treated with modified Yuebi and Banxia Decoction based on the treatment of the control group.The two groups were treated for 2 months.The clinical effects in both groups were evaluated;the traditional Chinese medicine(TCM)syndrome scores,lung function,scores of Airways Questionnaire 20-rised(AQ20R)and Asthma Control Questionnaire-5(ACQ-5),airway hyperresponsiveness,and levels of intercellular adhesion molecule-1(ICAM-1)and eosinophils(EOS)were compared between the two groups and the drug safety was also evaluated.Results:The total effective rate was 97.00%in the observation group,higher than that of 87.00%in the control group(P<0.05).After treatment,all TCM syndrome scores in both groups were decreased when compared with those before treatment,and all TCM syndrome scores in the observation group were lower than those in the control group(P<0.05).After treatment,the forced expiratory volume in one second as a percentage of expected value(FEV1%),and ratio of forced expiratory volume in one second and forced vital capacity(FEV1/FVC)in the two groups were increased when compared with those before treatment,and the scores of AQ20-R and ACQ-5 were decreased when compared with those before treatment(P<0.05);the FEV1%and FEV1/FVC in the observation group were higher than those in the control group,and the scores of AQ20-R and ACQ-5 were lower than those in the control group(P<0.05).After treatment,the minimum cumulative dose required for a 20%decrease in FEV1(PD20-FEV1)in both groups was higher than that before treatment,and the increases in FEV1
作者
刘中友
郑晓娜
LIU Zhongyou;ZHENG Xiaona
出处
《新中医》
CAS
2023年第9期53-58,共6页
New Chinese Medicine
关键词
哮喘
热哮证
越婢加半夏汤
肺功能
气道高反应性
细胞间黏附分子-1
嗜酸性粒细胞
Asthma
Heat-wheezing syndrome
Yuebi and Banxia Decoction
Lung function
Airway hyperresponsiveness
Intercellular adhesion molecule-1
Eosinophils
